Stocks / Stock overview

Novo Nordisk A S (NVO)

Quote, stock score, analyst consensus, and SEC filings, plus insider and Congress trades when there are any.

$37.82Price
-2.70%Day change
$166.69BMarket cap
1Our articles

Aft $37.90 (+0.21%)

NYSE · Price as of · Nasdaq Real Time Price

Stock Scorer
Scoring…
Analyst consensus
Hold$45.69
  • Analysts12
  • Implied upside+20.8%
  • Target range$39.36 to $63.96
Analyst estimates are opinions, not forecasts of what the stock will do.
Source: Yahoo Finance consensus, retrieved
Next earnings
February 3, 2027before the open
NVO reports in DKK, so we show the date only rather than presenting a consensus in another currency as dollars.
Beat the estimate in 3 of the last four quarters.
Source: Yahoo Finance earnings calendar

How Congress has done in NVO

Source: AIStockWire, scored from STOCK Act disclosures against daily price historyGenerated

Every purchase of NVO disclosed by a member of Congress in the last 5 years, scored over the 12 months after the trade date against SPY over the same window.

MeasureNVOSPY
Median 12-month return after purchase-16.4%+17.9%
Median difference vs SPY-34.4%—
Purchases that beat SPY0 of 12 (0%)—
Members who bought4—

Most frequent buyers: Scott Franklin (4), Lisa McClain (3), Marjorie Taylor Greene (3), Michael McCaul (2).

These are not returns anyone actually earned. Disclosures report a dollar bracket and no share count, so every purchase is counted once and weighted equally, and sales are not matched back to the buys that opened them. 6 of the 12 purchases are disclosed as a spouse's or dependent's rather than the member's own. Purchases from the last 12 months are excluded because their window has not closed yet.

Congress trades in NVO

Source: STOCK Act disclosures filed with the House and SenateLatest disclosed

DateMemberActionAmount
2026-09-10Kevin Hern OKSale$1,001 - $15,000
2026-08-31Kevin Hern OKSale (Partial)$1,001 - $15,000
2026-08-26Scott Franklin FLPurchase$1,001 - $15,000
2026-03-30Alan Armstrong OKPurchase$15,001 - $50,000
All congress trades

SEC filings

Source: SEC EDGAR

No current EDGAR filings resolved for NVO. Foreign and over-the-counter listings often do not file with the SEC.

Articles that mention Novo Nordisk A S without it being the main subject.

Anthropic puts $100 million into training 10,000 engineers from Accenture (ACN) and other companies
News

Anthropic puts $100 million into training 10,000 engineers from Accenture (ACN) and other companies

Anthropic's new academy aims to train 10,000 engineers by the end of 2027. Its first program borrows from the way doctors are trained.

Oct 2, 2026

Frequently asked questions

When does NVO report earnings?

Novo Nordisk A S (NVO) is scheduled to report quarterly results on February 3, 2027, before the open. Its results are reported in DKK, so we show the date only rather than presenting a consensus in another currency as dollars. It has beaten the consensus EPS estimate in 3 of the last four quarters.

What do analysts expect for NVO?

12 analysts cover Novo Nordisk A S (NVO). The consensus rating is Hold. The average price target is $45.69, in a range of $39.36 to $63.96.

Are insiders buying or selling NVO?

We have no qualifying Form 4 insider purchases or sales on record for Novo Nordisk A S (NVO). Sales are only tracked above a dollar threshold, so small routine trades may not appear.

Has Congress made money trading NVO?

4 members of Congress have disclosed buying NVO in the last 5 years, 12 purchases in total. Measured over the 12 months after each trade date, the median purchase returned -16.4% against +17.9% for SPY over the same windows, and 0 of the 12 (0%) beat the index. These are not returns anyone actually earned: congressional disclosures report a dollar bracket and no share count, so each purchase is counted once and weighted equally, and later sales are not matched back to the buys that opened them.

Where can I see NVO SEC filings?

We could not resolve current EDGAR filings for NVO. This usually means the ticker is a foreign or over-the-counter listing that does not file with the SEC.

Data on this page comes from SEC EDGAR, public disclosure feeds and market data providers, and may be delayed or incomplete. Nothing here is investment advice.